Lucid Capital initiated coverage of Monopar Therapeutics (MNPR) with a Buy rating and $71 price target Monopar is developing a Phase 3 drug for Wilson disease and radiopharmaceuticals to directly target tumors with minimal systemic side effects, the analyst tells investors in a research note. The firm assumes ALXN-1840 could be approved in 2026 and launched in 2027 in the U.S.. In 2035, the drug could achieve about $220M in sales in the U.S., contends Lucid.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR: